Boehringer Ingelheim Announces 2023 GRANTS Recipients

Duluth, Ga. -- Boehringer Ingelheim Animal Health announced today the 2023 award recipients for the Growing Research and New Technology for Swine (GRANTS) program. This year marks the 20th anniversary of the program, which funds critical, field-applicable research into swine health and production. This year's GRANTS recipients will receive $35,000 each to fund new advancements in porcine reproductive and respiratory syndrome virus (PRRSV) risk factors and diagnostics, as well as RNA virus stabilization strategies.

"The swine industry has evolved immensely over the last 20 years, due, in part, to the knowledge generated by this program and the incredible collaboration among the researchers," said Reid Philips, DVM, Senior Technical Manager for PRRS at Boehringer Ingelheim. "This year's GRANTS program recipients have great vision as they look to battle some of the biggest challenges facing the swine industry today."

Six independent swine veterinarians and researchers, who together make up the Swine Research and Technology Review Board, reviewed many exceptional proposals before making a final decision.

Boehringer Ingelheim congratulates the following 2023 GRANTS recipients:

· Jeff Zimmerman, DVM, Ph.D., Iowa State University, Ames, Iowa

· "Proof of concept: Strategies to stabilize RNA viruses in oral fluids"

· Daniel Linhares, DVM, MBA, Ph.D., Iowa State University, Ames, Iowa

· "Predictive value of PRRSV qPCR results from sow tonsil-oral-scraping (TOSc) samples for neonatal litter PRRSV status"

· Alyssa Betlach, DVM, Ph.D., Swine Vet Center, St. Peter, Minnesota

· "Assessing the role of gilt-related risk factors for PRRSV time-to-low-prevalence"

Boehringer Ingelheim has supported more than 70 research projects since the GRANTS program's inception in 2003. Across multiple evolutions of this program, more than $1.8 million has been given in support of the development of less costly, innovative diagnostic testing and sampling processes; identified more effective biosecurity practices; helped the industry better understand key diseases; and developed risk assessment tools, intervention programs, and vaccination strategies.

Applications for the 2024 GRANTS program will be open for submission in early 2024. For more information on how the GRANTS program is advancing the swine industry's knowledge of diseases and new technology through game-changing research, tools and more, visit

Research content is solely the responsibility of the authors and does not necessarily represent the official views of the Swine Research and Technology Review Board or Boehringer Ingelheim.

About the Swine Research and Technology Review Board

The Swine Research and Technology Review Board, an independent group of swine veterinarians and researchers, selects GRANTS recipients annually. Board members for the 2023 award selection process include:

· Daryl Olsen, DVM, AMVC

· Montse Torremorell, DVM, Ph.D., University of Minnesota

· Darin Madson, DVM, Ph.D., JBS Live Pork

· William Hollis, DVM, Carthage Veterinary Service, Carthage Ltd.

· Emily McDowell, DVM, Veterinarian, Pipestone Veterinary Service

· Jessica Davenport, DVM, 2023 AASV Young Swine Veterinarian of the Year, JBS Live Pork

About Boehringer Ingelheim Animal Health USA

Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, producers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock.

As a global leader in the animal health industry and as part of the family-owned Boehringer Ingelheim, we take a long-term perspective. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both.

Boehringer Ingelheim Animal Health has deep roots in the U.S. From a start in St. Joseph, Missouri, more than 100 years ago, it has grown to encompass seven sites. Boehringer Ingelheim Animal Health's portfolio contains widely used and well-respected vaccines, parasite-control products, and therapeutics for pets, horses, and livestock.

Source: Boehringer Ingelheim news release